Skip to content

Goodwill at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$21.74B0.0%
Eli Lilly logo
Eli LillyLLY
$6.13B+6.2%
Pfizer logo
PfizerPFE
$71.41B+4.3%
Merck & Co. logo
Merck & Co.MRK
$21.58B-0.5%
Amgen logo
AmgenAMGN
$18.67B+0.2%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.91B+479%
Enterprise value$38.63B+498%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s goodwill?
Revolution Medicines, Inc. (RVMD) reported goodwill of $14.61M in Q1 2026.
How has Revolution Medicines, Inc.'s goodwill changed year-over-year?
Revolution Medicines, Inc.'s goodwill decreased by 0.0% year-over-year, from $14.61M to $14.61M.
What is the long-term trend for Revolution Medicines, Inc.'s goodwill?
Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $14.61M to $14.61M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.